Zimmer Biomet Announces Fourth Quarter and Full-Year 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Zimmer Biomet (ZBH) PT Raised to $146 at Leerink Partners
January 31, 2018 7:50 AM ESTLeerink Partners raised its price target on Zimmer Biomet (NYSE: ZBH) to $146.00 (from $142.00) while maintaining a Outperform rating.
Analyst Richard Newitter commented, "Our OP rating is predicated on the view that for longer-term oriented investors we believe ZBH is a turnaround... More
Zimmer Biomet (ZBH) PT Raised to $155 at Needham & Company
January 30, 2018 1:11 PM ESTNeedham & Company raised its price target on Zimmer Biomet (NYSE: ZBH) to $155.00 (from $144.00) while maintaining a Strong Buy rating following in-line Q4 results.
Analyst Mike Matson commented, "ZBH's 4Q17 revenue beat and EPS met consensus and 1Q18 guidance was below consensus. Margins... More
Zimmer Biomet Holdings (ZBH) Reports In-Line Q4 EPS; Guides Q1 Modestly Below the Street
January 30, 2018 7:02 AM ESTZimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $2.10, in-line with the analyst estimate of $2.10. Revenue for the quarter came in at $2.07 billion versus the consensus estimate of $2.03 billion.
GUIDANCE:
Zimmer Biomet Holdings sees Q1 2018 EPS of $1.84-$1.91, versus the... More
